UCLA Discovers First Drug to Replicate Stroke Rehabilitation Effects in Mice
Original: UCLA discovers first stroke rehabilitation drug to repair brain damage (2025) View original →
The Gap in Stroke Treatment
Stroke is the leading cause of adult disability, yet no recovery drug exists. Physical rehabilitation remains the only standard treatment - limited in effectiveness and hard for most patients to sustain at the necessary intensity.
The Discovery
A UCLA Health research team led by Dr. S. Thomas Carmichael identified that stroke damages brain connections far beyond the site of injury. Specifically, it disrupts parvalbumin neurons - cells critical for maintaining brain rhythm - in remote brain areas.
The team developed two candidate drugs targeting this mechanism. DDL-920, developed in Dr. Varghese John's lab, produced significant recovery in movement control after stroke in mice - the first drug to achieve what physical rehabilitation achieves.
Why This Matters
Published in Nature Communications, this research opens a path toward a stroke recovery drug patients could take at home. It doesn't eliminate the need for rehabilitation, but pharmacological support could dramatically improve outcomes for the majority of stroke patients who can't access intensive therapy. Clinical trials in humans are the next step.
Related Articles
The deal is worth up to about $600M, with roughly $60M in initiation fees, near-term payments, and milestones. Insilico will use Pharma.AI for early discovery while Takeda takes selected candidates into clinical validation and global development.
Anthropic is not only selling Claude Science as a research workbench. It says it wants to discover treatments for neglected diseases, raising a harder question: can a frontier AI lab become both a pharma software vendor and a drug developer?
Meta said on March 26, 2026 that TRIBE v2 is a foundation model for predicting human brain responses to sight, sound, and language. The supporting paper and demo highlight zero-shot generalization, prediction across 70,000 voxels, and public releases of the paper, code, and model weights.